Editas Medicine, Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. On July 18, 2022, we granted our Chief Medical Officer an option to purchase 171,602 shares of our common stock as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). No underwriters were involved in the foregoing issuance of securities. The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. The recipient either received adequate information about us or had access, through other relationships, to such information. The stock option is scheduled to become exercisable as to 25% of the shares underlying the options on the first anniversary of the date of grant, and as to an additional 2.0833% of the shares underlying the option at the end of each successive month following such date, subject to the recipient’s continued service. The option has an exercise price of $14.99 per share. 32 Table of Contents Item 6. Exhibits ​ Exhibit Index ​ Exhibit Number Description of Exhibit 31.1* ​ Rule 13a-14(a) Certification of Principal Executive Officer 31.2* ​ Rule 13a-14(a) Certification of Principal Financial Officer 32.1+ ​ Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350 101* ​ The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations (unaudited), (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited), (v) Condensed Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags. 104* ​ The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL. ​ ​ * Filed herewith + The certifications furnished in Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications are not to be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference. ​ ​ 33 Table of Contents SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ ​ ​ ​ ​ EDITAS MEDICINE, INC. ​ ​ ​ ​ ​ ​ Dated: November 2, 2022 By: /s/ Michelle Robertson ​ ​ Michelle Robertson ​ ​ Chief Financial Officer (Principal Financial Officer) ​ ​ ​ ​ 34